New to Meducation?
Sign up
Already signed up? Log In
view moderators

TissuePlasminogenActivator

Category

Preview
0
2

WDYS: Talking about tPA | Ed in the ED

The use of Alteplase (tPA) in the setting of ischemic stroke has grown to be one of the most controversial issues in emergency medicine and for good reason. It is a trifecta of hardship: time is limited, the evidence for treatment is unclear, and patients are especially vulnerable to the information we provide when making a life changing decision. Unfortunately, most patients have not kept tabs on the literature, and when their health is on the line it is up to you to lay out their options for care.  
edintheed.com
over 6 years ago
Www.bmj
0
18

Authors’ reply to Wardlaw and Berge

Wardlaw and Berge note the use of data from all thrombolytic trials and alteplase trials, and that distinguishing between these conclusions could be a source of confusion.1 Either way, we question the validity of “up to six hours” or “up to 4.5 hours” conclusions because:  
feeds.bmj.com
over 6 years ago
Preview
0
9

'Clot-busting' drug could be used more widely for stroke patients, study suggests

There are concerns that for some patients, the clot-busting drug alteplase may increase the risk of a brain bleed. However, a new study claims it is safer than previously believed.  
medicalnewstoday.com
over 6 years ago
Preview
0
1

Women and men have different exclusion criteria for rtPA

After analyzing stroke treatment records, researchers at Rhode Island Hospital in collaboration with researchers from the University of Cincinnati learned that women and men have different reasons for being excluded from receiving the common clot-dissolving drug, recombinant tissue plasminogen activator. Importantly, more women had very high blood pressures, which reduced their eligibility to be treated with the highly effective drug. The study was recently published in the American Heart Association's journal, Stroke.  
eurekalert.org
over 6 years ago